Table 4.

Psoriasis Symptom Inventory and Dermatology Life Quality Index (DLQI) threshold scores over time

		Brodalumab
		Q2W			Q4W
	Placebo (n = 38)	70 mg (n = 39)	140 mg (n = 39)	210 mg (n = 40)	280 mg (n = 42)
Proportion of subjects with Psoriasis Symptom Inventory total score = 0
Baseline
n/N (%)	0/33 (0)	0/37 (0)	0/37 (0)	0/39 (0)	0/42 (0)
P-value		N/A	N/A	N/A	N/A
Week 2
n/N (%)	0/34 (0)	4/38 (10)	2/36 (6)	4/38 (10)	6/41 (15)
P-value		0·047	0·154	0·043	0·020
Week 4
n/N (%)	0/37 (0)	2/38 (5)	6/39 (15)	14/40 (35)	9/41 (22)
P-value		0·161	0·012	< 0·0001	0·002
Week 8
n/N (%)	0/37 (0)	6/38 (16)	17/39 (44)	20/40 (50)	7/41 (17)
P-value		0·012	< 0·0001	< 0·0001	0·007
Week 12
n/N (%)	0/37 (0)	7/38 (18)	16/39 (41)	22/40 (55)	13/41 (32)
P-value		0·006	< 0·0001	< 0·0001	0·0001
Proportion of subjects with DLQI total score = 0
Baseline
n/N (%)	0/37 (0)	0/37 (0)	0/39 (0)	0/40 (0)	1/42 (2)
P-value		N/A	N/A	N/A	0·341
Week 4
n/N (%)	0/36 (0)	3/38 (8)	8/39 (20)	14/39 (36)	8/40 (20)
P-value		0·088	0·004	< 0·0001	0·004
Week 8
n/N (%)	0/37 (0)	5/38 (13)	17/39 (44)	21/40 (52)	10/41 (24)
P-value		0·023	< 0·0001	< 0·0001	0·0009
Week 12
n/N (%)	0/37 (0)	6/38 (16)	18/39 (46)	23/40 (58)	14/41 (34)
P-value		0·012	< 0·0001	< 0·0001	< 0·0001
Proportion of subjects with DLQI total score = 0/1
Baseline
n/N (%)	0/37 (0)	0/37 (0)	2/39 (5)	0/40 (0·0)	2/42 (5)
P-value		N/A	0·161	N/A	0·175
Week 4
n/N (%)	2/36 (6)	8/38 (21)	14/39 (36)	22/39 (72)	12/40 (30)
P-value		0·054	0·002	< 0·0001	0·006
Week 8
n/N (%)	2/37 (5)	9/38 (24)	24/39 (62)	29/40 (72)	18/41 (44)
P-value		0·026	< 0·0001	< 0·0001	< 0·0001
Week 12
n/N (%)	2/37 (5)	10/38 (26)	25/39 (64)	29/40 (72)	23/41 (56)
P-value		0·015	< 0·0001	< 0·0001	< 0·0001

P-value is based on Cochran–Mantel–Haenszel test stratified by body mass index group (≤ 35, > 35) and is for comparison between each brodalumab group and placebo without multiplicity adjustment; last observation carried forward was used to impute missing data. N/A, not applicable; Q2W, every 2 weeks; Q4W, every 4 weeks.